Related Experiment Video
Updated: Aug 17, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Cancer vaccines and immunotherapies: emerging perspectives
Robert A Henderson1, Sally Mossman, Natalie Nairn
1Corixa Corporation, 1900 9th Avenue, Suite 1100, Seattle, WA 98104, USA. robert.henderson@corixa.com
Abstract:
Research efforts over the last two decades studying immune responses to human carcinomas have demonstrated that antigens expressed by tumor cells can elicit specific cellular and humoral immune responses. Unfortunately, despite the observation that existent immune responses to these antigens are present in some patients with cancer, the tumors continue to progress. Thus, there has been considerable interest to augment these immune responses by immunization. Some of the clinical trials of the first cancer vaccines have provided evidence of clinical benefit thus encouraging the development of other vaccines. Challenges to development of such cancer vaccines include the identification and characterization of the antigen(s) to be targeted, the definition of the desired immune response to be elicited by the vaccine, and the choice of the appropriate vaccine delivery system.
Insights
Cancer vaccines aim to boost natural immune responses against tumor antigens. Despite existing immune activity, tumors progress, necessitating vaccine development for improved cancer treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Cancer Vaccine Development
Background:
- Research shows tumor cells express antigens that trigger immune responses in cancer patients.
- Existing anti-tumor immunity is often insufficient to halt cancer progression.
- This highlights the need for strategies to enhance anti-tumor immune responses.
Purpose of the Study:
- To review the progress and challenges in developing cancer vaccines.
- To discuss the potential of augmenting existing immune responses through immunization.
- To explore key considerations for future cancer vaccine design.
Main Methods:
- Review of research on immune responses to human carcinomas over the past two decades.
- Analysis of clinical trial data from early cancer vaccine studies.
- Identification of critical factors in cancer vaccine development.
Main Results:
- Tumor antigens can elicit specific immune responses in some cancer patients.
- Early cancer vaccine trials show promise and clinical benefit.
- Tumor progression occurs despite detectable immune responses.
Conclusions:
- Cancer vaccines hold promise for augmenting anti-tumor immunity.
- Key challenges include identifying target antigens, defining desired immune responses, and selecting delivery systems.
- Further research and development are crucial for effective cancer vaccine strategies.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...